VVP
TEVA icon

Venture Visionary Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Venture Visionary Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,276
Closed -$9.6K – 1427
2022
Q2 		$9.6K Buy
+1,276
New +$11.1K ﹤0.01% 1254

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Venture Visionary Partners's TEVA Position: Q3 2022 in Review

Venture Visionary Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 1,276 shares — an estimated $9.6K sold.

Venture Visionary Partners first reported a position in TEVA in Q2 2022 and held it in 1 quarter. The position peaked at $9.6K in Q2 2022. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Venture Visionary Partners reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 1,276 Teva Pharmaceuticals shares in Q3 2022, an estimated $9.6K.
  • Venture Visionary Partners first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Teva Pharmaceuticals position peaked at $9.6K in Q2 2022.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.